What Eupraxia Pharmaceuticals Inc. does

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company founded in 2012 and headquartered in Vancouver/Victoria, British Columbia, Canada, publicly traded on NASDAQ and TSX under the ticker EPRX. The company develops targeted, locally delivered anti-inflammatory therapies using its proprietary Diffusphere™ extended-release drug delivery platform, which coats an active compound with a micron-thin polymer membrane designed to release drug at a defined, constant rate directly at the site of disease while minimizing systemic exposure. Two clinical candidates anchor the pipeline: EP-104GI, a long-acting controlled-release fluticasone propionate formulation injected into esophageal tissue for eosinophilic esophagitis (EoE), currently in the Phase 1b/2 RESOLVE trial with 1-year durability data showing two-thirds of Cohort 5 patients in clinical remission; and EP-104IAR, a long-acting controlled-release fluticasone propionate formulation injected intra-articularly for knee osteoarthritis (OA), which has completed the Phase 2 SPRINGBOARD trial.\n\nThe company is pre-revenue with no commercialized products, no disclosed pricing, and revenue dependent entirely on future regulatory approval and launch. Eupraxia's go-to-market motion is enterprise field sales, currently being built out via a Seattle-based US subsidiary and a Vice President of Market Development and Commercial Strategy role focused on KOL, patient-advocacy, and gastroenterology/allergist/pediatric subspecialist engagement ahead of EP-104GI approval. The company maintains wholly-owned operating subsidiaries in the United States (Eupraxia Pharma, Inc.; Eupraxia Pharmaceuticals USA, LLC; Eupraxia Holdings, Inc.) and Australia (Eupraxia Pharmaceuticals Australia PTY Ltd.), employs approximately 40 people, and reports a combined addressable market of $10B+ across EoE (approximately 500,000 US patients, projected to exceed 1 million by 2029) and knee OA (more than 30 million US patients). Leadership comprises CEO James A. Helliwell, CFO Alex Rothwell, CMO Dr. Jeymi Tambiah, EVP R&D Alex Therien, and a board chaired by Simon Pimstone, with a clinical advisory board chaired by Dr. Evan Dellon.

Name

Eupraxia Pharmaceuticals Inc.

Legal name

Eupraxia Pharmaceuticals Inc.

Website

https://eupraxiapharmaceuticals.com

Company type

Public

Operating status

Operating

Headcount range

11–50 employees

Short description

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing targeted extended-release therapies using its proprietary Diffusphere™ drug delivery platform for eosinophilic esophagitis and knee osteoarthritis, currently pre-revenue with two Phase-stage candidates advancing toward US commercialization.

Ownership category

akta.pro rank

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotechnology company with no commercialized products. The company is developing targeted therapies leveraging its proprietary Diffusphere technology for eosinophilic esophagitis and knee osteoarthritis. Revenue will be generated through product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing targeted therapies that leverage its proprietary Diffusphere™ extended-release drug delivery technology. The technology coats an active compound with a micron-thin polymer membrane designed to release the drug at a constant rate directly at the site of disease. The company has two clinical-stage candidates: EP-104GI, a long-acting controlled-release fluticasone propionate formulation for eosinophilic esophagitis (EoE), and EP-104IAR, a similar formulation for knee osteoarthritis (OA).

Product overview

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company with a single proprietary technology platform called Diffusphere™. This extended-release drug delivery platform underpins their clinical pipeline, which currently consists of two clinical candidates: EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis. Both candidates leverage the Diffusphere technology to deliver fluticasone propionate locally at the site of disease with sustained release, potentially reducing systemic side effects and improving treatment outcomes compared to conventional therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Diffusphere™ Extended-Release Delivery Platform

Quantifiable outcome

• At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GI
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered supporting.

• APFED (American Partnership for Eosinophilic Disorders)supportingOthersA U.S.-based nonprofit founded in 2001, dedicated to improving EoE patient and family lives through education, advocacy, and research support. Listed as a patient resource on Eupraxia's website.
• ausEE (Australian Eosinophilic Diseases Association)supportingOthersA volunteer-run national charity in Australia (also serving New Zealand) providing resources, awareness campaigns, and peer support for those affected by eosinophilic disorders.
• CDHF (Canadian Digestive Health Foundation)supportingOthersA leading Canadian charity offering trustworthy educational content and support for individuals managing digestive diseases, including EoE.
• EOS NetworksupportingOthersA UK-based global nonprofit fostering patient, professional, and research collaboration around EGIDs such as EoE, offering resources and awareness initiatives.
• EUREOS (European Society for Eosinophilic Oesophagitis)supportingOthersA European network of healthcare professionals delivering clinical guidelines, continuing education, and updates on EoE research and patient care.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sanofi: Sanofi co-develops and commercializes Dupixent (dupilumab) with Regeneron, which is approved for Eosinophilic Esophagitis and represents the principal competing therapy Eupraxia's lead asset must differentiate against.
• Regeneron Pharmaceuticals: Regeneron co-developed Dupixent (dupilumab) with Sanofi, the first systemic biologic approved for EoE. Its competitive position in the EoE therapeutic class makes it a direct comparator for EP-104GI commercial positioning.
• Heron Therapeutics: Heron develops long-acting, site-specific injectable products such as Zynrelef for post-surgical pain and Sustol for CINV. Its approach of extended-release injectable delivery at the site of action parallels the Diffusphere™ strategy.
• Endo International: Endo is a specialty pharmaceutical company with a focus on injectable and locally-acting drug delivery products, including Xiaflex. Its orientation toward specialty injectable therapeutics makes it a direct comparator on both technology and commercialization approach.
• Pacira BioSciences: Pacira commercializes EXPAREL (long-acting local anesthetic) and owns Flexion's Zilretta (intraarticular steroid for knee OA). It is the most direct peer to Eupraxia given its focus on long-acting, site-specific injectable formulations for inflammatory and pain indications.

Broad incumbents

• Eli Lilly: Lilly markets a broad inflammation and immunology portfolio (e.g., Taltz, Ebglyss). Its scale in immunology and biologics establishes it as a broad incumbent competitive backdrop for Eupraxia's inflammation-focused pipeline.
• Pfizer: Pfizer acquired Arena Pharmaceuticals primarily for etrasimod, an oral S1P modulator pursued for EoE, positioning Pfizer as a broad incumbent competing for the same patient population targeted by EP-104GI.
• AstraZeneca: AstraZeneca markets Tezspire (tezepelumab) and other respiratory/inflammation biologics, some of which are pursuing EoE indications, making it a broad incumbent comparator to Eupraxia's lead asset.
• Takeda Pharmaceutical: Takeda is developing Fasenra (benralizumab) in EoE and markets a broad gastroenterology and inflammation portfolio, positioning it as a competing therapy provider across both of Eupraxia's addressable indications.
• GSK: GSK commercializes Nucala (mepolizumab), which has been evaluated in EoE. Its established inflammation/respiratory biologics portfolio makes it a broad incumbent comparable to Eupraxia on competitive context.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Eupraxia_Pharma
• LinkedInlinkedin.com/company/eupraxia-pharmaceuticals-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eupraxia Pharmaceuticals Inc.